Treatments:Dipeptidyl Peptidase-4 Inhibitor Pharmacokinetics

From Proteopedia

References for Dipeptidyl Peptidase-4 Inhibitor Pharmacokinetics ^[1][2]

1. ↑ Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010 Aug;12(8):648-58. PMID:20590741 doi:10.1111/j.1463-1326.2010.01212.x
2. ↑ Augeri DJ, Robl JA, Betebenner DA, Magnin DR, Khanna A, Robertson JG, Wang A, Simpkins LM, Taunk P, Huang Q, Han SP, Abboa-Offei B, Cap M, Xin L, Tao L, Tozzo E, Welzel GE, Egan DM, Marcinkeviciene J, Chang SY, Biller SA, Kirby MS, Parker RA, Hamann LG. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2005 Jul 28;48(15):5025-37. PMID:16033281 doi:10.1021/jm050261p